A new analysis from the COMMANDS trial of erythroid maturation agent luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) shows not only sustained, longer-term benefits over ...

The novel therapeutic agents luspatercept and imetelstat have been particularly impactful. Luspatercept, which is effective in lower-risk (LR)-MDS, especially but not only in SF3B1- mutated cases, ...

Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes ...

Luspatercept, an erythroid maturation agent, promotes late-stage erythroblast expansion and differentiation, enhancing red blood cell production. 2 The study defined the primary end point as the ...

The findings, scheduled for presentation at ASCO Annual Meeting, showed luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) — an erythroid maturation agent — provided significantly longer ...

The positive opinion Jan. 27 from the EMA’s Committee for Medicinal Products for Human Use regarding Reblozyl (luspatercept) from Bristol Myers Squibb Co. to treat adults with ...

Investigating the process of reticulocyte maturation to erythrocytes in vitro Investigating macrophage behaviour and interactions within erythroblastic islands Ex vivo culture of neutrophils to ...

Erythroid maturation-dependent remodelling of CTLH E3 complex, along with its cognate E2, controls the orderly progression of human erythropoiesis, thus establishing a paradigm for other E2-E3 ...

Late-stage progenitor maturation arrest, their expansion, and missing egress from BM are observed, possibly mediated by negative regulators of erythropoiesis, eg, transforming growth factor-β ...